Direct oral anticoagulants doacs such as the direct factor xa inhibitors rivaroxaban, apixaban, edoxaban or the direct thrombin inhibitor dabigatran are attractive treatment options for hit 811 for several reasons. Targets of parenteral anticoagulants the targets of parenteral anticoagulants in current use or in development are depicted in figure 1. The main use of anticoagulants is to prevent thrombus formation or extension of an existing thrombus in the slowermoving venous side of the circulation, where the thrombus consists of a fibrin web enmeshed with platelets and red cells. Ufh is a heterogeneous mixture of glycosaminoglycans that bind to antithrombin via a. Differentiation of parenteral anticoagulants in the. American society of hematology 2018 guidelines for. Recommended parenteral anticoagulant agents with different indications for the prevention and treatment of venous thromboembolism include unfractionated heparin, lowmolecularweight heparins and fondaparinux. Antithrombotic and thrombolytic therapy for valvular disease.
Garcia da, baglin tp, weitz ji, samama mm, american college of chest physicians. A detailed description of coagulation targets has been provided in section i of this series 3. American college of chest physicians the antithrombotic therapy and prevention of thrombosis, 9th ed. Heparin is typically the preferred agent for inpatient parenteral anticoagulation. Methods we generated strong grade 1 and weak grade 2 recommendations based on highquality grade a, moderatequality grade b, and lowquality grade c evidence. Intrinsic pathway extrinsic pathway tissue injury blood vessel injury recall. These agents can be divided into indirect anticoagulants whose activity is mediated by plasma cofactors and direct anticoagulants that do.
Appendix b treatment of bleeding associated with parenteral anticoagulants. A challenge for hospital formularies will be to manage the use of direct oacs from hospital to outpatient settings. Transferring from parenteral anticoagulants to warfarin. Anticoagulants are among the most frequently prescribed medications in the us. Antithrombotic therapy and prevention of thrombosis, 9th ed. Brahma department of pharmacology neigrihms, shillong 2. Xiia xii thromboplastin xia xi ixa ix viia xa x factors affected by heparin prothrombin vit. The new accp guidelines on antithrombotic therapy have arrived. The goal of bridging therapy with parenteral heparin either ufh or lmwh, usually in therapeutic doses, is to allow for continued anticoagulation during temporary discontinuation of vitamin k antagonist vka therapy, usually for an elective procedure or surgery this makes intuitive sense. In patients with an intermediate clinical with parenteral anticoagulants compared with no treatment if the results of diagnostic tests are expected to be delayed for more than 4. Learn vocabulary, terms, and more with flashcards, games, and other study tools.
As of this recording the guidelines are available online in a prepublication online first pdf document. New antiplatelet drugs and new oral anticoagulants bja. American college of chest physicians evidencebased clinical practice guidelines chest 2012. The prevention of venous thromboembolism has been identified as a leading priority in hospital safety. Key management strategies for optimal use of anticoagulants include initial anticoagulant dose selection recommendation 1, druginteraction management recommendation 2, pointofcare international normalized ratio inr testing recommendations 3 and 4, inr recall interval selection recommendations 5 and 6, laboratory monitoring of the. Results for acute dvt or pulmonary embolism pe, we recommend initial parenteral anticoagulant therapy grade 1b or anticoagulation with rivaroxaban. For acute treatment of venous thromboembolism and during revascularization therapy, immediately acting parenteral anticoagulants are used. Prescribing decisions in venous thromboembolism management. Vte affects as many as 500,000 people in the us annually, and it is estimated that more than 1. American college of chest physicians evidencebased clinical practice guidelines author links open overlay panel david a. First, there is no potentially deleterious immunologic interaction between these agents and hit antibodies. Switch from oral anticoagulants to parenteral heparin in sars. European heart rhythm association practical guide on the use of new oral anticoagulants in patients with nonvalvular atrial fibrillation 20 15, 625651. The indirect parenteral anticoagulants in current use include heparin, lowmolecularweight heparins lmwhs, fondaparinux, and danaparoid.
This article describes the pharmacology of approved parenteral anticoagulants. Atrial fibrillation affects 700 to 775 per 100,000 people in the us. More recently, new oral anticoagulant drugs, namely the direct thrombin inhibitor dabigatran etexilate and the direct factor xa inhibitor rivaroxaban, have been approved for clinical use in several. Switch from oral anticoagulants to parenteral heparin in. Accp guidelines on laboratory and clinical monitoring and on reversal strategies.
American college of chest physicians evidencebased clinical practice guidelines david a. Parenteral anticoagulants are routinely indicated for the prevention and treatment of venous thromboembolism. American college of chest physicians evidencebased clinical practice guidelines differs substantially from the prior versions both in process and in content. American college of chest physicians evidencebased clinical practice. Monitoring fondaparinux in the setting of antithrombin. Intravenous heparin flushes are widely used to keep peripheral and indwelling lines patent. Chest supplement parenteral anticoagulants antithrombotic therapy and prevention of thrombosis, 9th ed. There is no evidence that heparin flushes have any advantage over normal saline for keeping peripheral. As they did in 2012, chest will publish a formatted version of the guidelines with shaded text used to highlight recommendations that are new or have been changed since the 9th edition was published.
American college of chest physicians evidencebased clinical practice guidelines. When warfarin is indicated for followup therapy after initial therapy with a parenteral anticoagulant e. Parenteral anticoagulants chest chest journal american. American college of chest physicians evidencebased. Antithrombotic therapy and prevention of thrombosis, 9th. Their uses include the treatment or prevention of venous thromboembolism and atrial fibrillation. In this introduction, we describe some of the differences and. Hirsh j, bauer ka, donati mb, gould m, samama mm, weitz ji. Anticoagulants inhibit the initiation and progress of coagulation and fibrinclot formation and propagation.
Antithrombotic therapy and prevention of thrombosis, 9th ed american college of chest physicians evidencebased clinical practice guidelines. These drugs have little or no intrinsic anticoagulant activity, and exert their anticoagulant activity by activating antithrombin at, an endogenous inhibitor of various activated clotting factors. The guidelines include recommendations on oral and parenteral anticoagulants and antiplatelet drugs, prevention and treatment of venous thromboembolism, perioperative management of antithrombotic therapy, and antithrombotic therapies for cardiovascular diseases. Select a term to see related articles anticoagulants arixtra dalteparin desirudin enoxaparin fondaparinux fragmin heparin iprivask lovenox venous thromboembolism warfarin. The american college of chest physicians is the global leader in advancing best patient outcomes through innovative chest medicine education, clinical research, and teambased care. Ufh is a heterogeneous mixture of glycosaminoglycans that bind to antithrombin via a unique.
Antithrombotic therapy for vte disease ui health care. Although thrombotic episodes are uncommon in childhood, anticoagulants may be required in children with congenital heart disease. American college of chest physicians evidencebased clinical practice guidelines this. The ideal anticoagulant medication is one that does not require frequent monitoring yet can be monitored if needed, welldefined pharmacokinetics no need to adjust dose for renal or hepatic impairment, ease of administration once daily oral dosing, the ability to easily reverse effect if needed, no food or drug interactions, and rapid onset and offset of action and costeffective therapy. Management of anticoagulation in the periprocedural. American college of chest physicians evidence based clinical practice guidelines. Among the direct oral anticoagulants, there are key differences including the need for parenteral anticoagulation leadin, once or twice per day dosing, and degree of renal excretion. Chest supplement, antithrombotic therapy and prevention of thrombosis, 9th edition, accp. The introduction of direct oral anticoagulants oacs for the treatment and prevention of thromboembolic disease represents a shift from the traditional vitamin k antagonistbased therapies, which have been the mainstay of treatment for almost 60 years.
Practice guidelines chest physicians evidencebased clinical. No part of this article or pdf by the american college of chest physicians, 3300 dundee road, physicians. These include the indirect anticoagulants, unfractionated heparin ufh, lowmolecularweight heparins lmwhs, fondaparinux, and danaparoid, as well as the direct thrombin inhibitors hirudin, bivalirudin, and argatroban. Background this article addresses the treatment of vte disease. There are risks in their use due to poor practice such as not being formally prescribing or part of a patient group direction. Accp guidelines this article focuses on parenteral anticoagulants in current use. American college of chest physicians evidencebased clinical practice guidelines 8th edition. Accp guidelines the eighth iteration of the american college of chest physicians antithrombotic guidelines presented, in a paper version, a narrative evidence sum. Clinical guidelines for anticoagulation in vte mainehealth. In patients with acute dvt of the leg, we recommend early initiation of vka eg, same day as parenteral therapy is started over delayed initiation, and continuation of parenteral anticoagulation for a minimum of 5 days and until.
209 1401 477 1121 72 442 1217 138 1347 1115 579 7 133 1242 1360 172 189 400 1494 1068 553 104 950 816 581 986 204 605 900 1087 946 1130 1212 544 394 280 647 829 437